We are proud to announce that our SME Instrument Phase 1 proposal has been awarded this competitive and prestigious grant from the European Community. Our ESR score of 13.91 placed us 89th among the 3275 applications filed in the last cut-off. This project will enable GlakoLens to conduct an in-depth technical and economic feasibility study culminating into an updated business plan focusing on global commercialization of our innovative technology.
The proprietary technology of GlakoLens will provide ophthalmologists with a powerful diagnostic tool, GlakoSense Platform, in the fight against glaucoma induced blindness. We are foreseeing a future where early diagnosis of ocular hypertension will prevent deterioration of quality of life due to sight loss and consequent economic and social burden on societies.